Want to join the conversation?
$DGX 2Q15 Q&A: Glen from Credit Suisse asked about volumes, and Steve replied, On an existing basis we feel utilization is stable versus the prior year. Also on drug remarks, we continue to steer our resources & our energy around higher profit portion of marketplace, & our top line growth focus is paying off better revenue per requisition.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.